Korro Bio is trading 6.4% lower at $11.28, with no specific cause established for the October 23 decline. - Available reports identified no fresh company-specific announcement explaining the move. - On October 22, Korro Bio reported positive preclinical KRRO-111 results: up to 96% RNA editing and a 95% reduction in liver Z-AAT in mice. Coverage linked the results to the previous-session rally. - Broader indices were mixed to lower and did not clearly explain the decline.